Recent Updates
Recently added Catalysts
ZURA Positive Sentiment

Zura Bio to Participate in the Cantor Global Healthcare Conference

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zura Bio Limited, a clinical-stage biotechnology company, will participate in the Cantor Global Healthcare Conference. The event is scheduled for September 9, 2026, in New York, NY. This participation underscores Zura's commitment to connecting with investors and discussing its innovative approaches to treating autoimmune and inflammatory diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zura Bio is actively engaging with investors.
  • Participation in a prominent healthcare conference highlights company visibility.
  • Focus on developing novel medicines for serious diseases shows commitment to innovation.

Full Press Release Details

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: Cantor Global Healthcare Conference Location: New York, NY Fireside chat: Wednesday, September 9, 2026, at 9

Frequently Asked Questions

When is Zura Bio participating in the conference?

Zura Bio will participate in the conference on September 9, 2026.

Where is the Cantor Global Healthcare Conference held?

The conference will be held in New York, NY.

What is Zura Bio's focus in biotechnology?

Zura Bio focuses on developing medicines for autoimmune and inflammatory diseases.

Who from Zura Bio will attend the conference?

Members of Zura Bio's management team will participate in the conference.

ShareAdd on Google
Tags: ZURA Viatris Investor Conferences Healthcare Zura Bio Cantor Global Healthcare Conference biotechnology autoimmune diseases investor conference
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$205M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Tibulizumab Dose APhase 2
Hidradenitis Suppurativa (HS) →